Real-world effectiveness and safety of pan-genotypic antiviral therapy for chronic HCV-infection: data from three clinical centers in St. Petersburg

   The aim of the analysis was to describe the results of administration of pan-genotype antiviral therapy (glecaprevir / pibrentasvir, GLE / PIB) in real-world setting in three clinical centers in St. Petersburg within the city program for the treatment of chronic hepatitis C.
   Materials and methods. A retrospective analysis of the GLE / PIB usage of in the period from 2019 to 2022 within the city program for the treatment of chronic hepatitis C in St. Petersburg was carried out.
   Results. The analysis included 464 patients treated in three clinical centers of St. Petersburg: St. Petersburg State Medical Institution “Clinical Infectious Diseases Hospital named after S. P. Botkin”, St. Petersburg State Medical Institution “Center for the Prevention and Control of AIDS and Infectious Diseases” and the Clinic of Infectious Diseases of the Military Medical Academy named after S. M.Kirov”. Overall 452 out of 464 patients (97 %) achieved SVR12. According to the duration of treatment, SVR12 rates were the following: 8 weeks – 97.7 % (419 / 429), 12 weeks – 92.9 % (26 / 28) and 16 weeks – 100 % (7 / 7). The effectiveness according to fibrosis stage was as follows: F0 – 97 % (142 / 146), F1 – 100 % (74 / 74), F2 – 100 % (59 / 59), F3 – 98 % (57 / 58), F4 (CP-A, B) – 94 % (118 / 125). SVR12 according to HCV genotypes and subtypes was the following: genotype 1b – 100 % (63 / 63), genotype 1a – 91 % (21 / 23), genotype 1 unspecified – 100 % (23 / 23), genotype 2 – 98 % (50 / 51), genotype 3 – 97 % (292 / 301). In patients with an indeterminate genotype, the efficacy was 100 % (7 / 7). Antiviral therapy was well tolerated, there were no cases of discontinuation of therapy, as well as cases of the development of serious adverse events.

   Conclusion. GLE / PIB has demonstrated high effectiveness in the real-world setting in patients infected with prevalent genotypes of HCV, including those with genotype 3 and compensated liver cirrhosis. The results of our analysis fully correspond to the data obtained earlier in clinical trials and
real-world setting.

1. WHO HCV Key Facts https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

2. WHO Global Hepatitis Programme https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/overview

3. Esaulenko E. V. Gepatit S v Rossii i Severo-Zapadnom federal’nom okruge: itogi pervogo etapa global’noj programmy eliminacii infekcii / Esaulenko E. V., Dzemova A. A., Trifonova G. F., Bushmanova i soavt. // VICH-infekciya i immunosupressii. – 2021. – T. 13, № 3. – S. 40–51.

4. Zhdanov K. V. Eliminaciya HCV-infekcii: istoriya s prodolzheniem / K. V. Zhdanov, K. V. Kozlov, V. S. Sukachev, S. M. Zaharenko i soavt. // Zhurnal infektologii. – 2018. – T. 10, № 4. – S. 6-13.

5. Chulanov V. P. Hronicheskij gepatit C kak problema zdravoohraneniya Rossii segodnya i zavtra / V. P. Chulanov, N. N. Pimenov, N. A. Mamonova, O. I. Sagalova i soavt. // Terapevticheskij arhiv. – 2015. – № 11. – S. 5-10.

6. M. I. Mihajlov. Virusnye gepatity – problema obshchestvennogo zdorov’ya v Rossijskoj Federacii / M. I. Mihajlov, N. D. Yushchuk, E. Yu. Malinnikova, K. K. Kyuregyan i soavt. // ORGZDRAV: Novosti. Mneniya. Obuchenie. Vestnik VSHOUZ, T. 12. № 2, 2018, S. 20-29.

7. Virusnye gepatity v Rossijskoj Federacii. Analiticheskij obzor. 11 vypusk / Pod red. V. I. Pokrovskogo, A. A. Totolyana. – SPb.: FBUN NIIEM imeni Pastera, 2018. – 112 s.

8. Gosudarstvennyj reestr lekarstvennyh sredstv (RF) [Internet], obrashchenie v noyabre 2022, dostupen po ssylke – grls.rosminzdrav.ru

9. Backih S. N. Bezinterferonovaya terapiya hronicheskogo gepatita S: smena preparatov ili novaya paradigma lecheniya? Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2014, T. 24 №. 4, S. 23-31.

10. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020 Nov; 73 (5): 1170-1218.

11. D. R. Nelson, J. N. Cooper, J. P. Lalezari et al, All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61 (4): 1127-35

12. G. R. Foster, N. Afdhal, S. K. Roberts et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373: 2608-2617

13. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C (AASLD & IDSA), [Internet], cited 2022 Nov 26. Available from: https://www.hcvguidelines.org/

14. G. Cabibbo, C. Celsa, C. Cammà et al. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? Liver International 2018; 38: 2108-2116.

15. Y.-H. Yen, C.-H. Chen, C.-H. Hung, et al. (2019) Active hepatocellular carcinoma is an independent risk factor of directacting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS ONE 14 (10): e0222605.

16. K. Drysdale, Y. Ntuli, J. Bestwick et. al. English hepatitis C registry data show high response rates to directly acting antivirals, even if treatment is not completed; Aliment Pharmacol Ther. 2020 Jul; 52 (1): 168-181.

17. A. Soria et. al. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort; Liver International 2020 Apr; 40 (4): 769-777